search
Back to results

Ventilator Monitoring in Early Exacerbation Detection

Primary Purpose

Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
iVAPS ventilation
Sponsored by
ResMed
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Respiratory Failure focused on measuring Non-Invasive Positive-Pressure Ventilation, Disease Exacerbation, Respiratory Failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with a diagnosis of obstructive (COPD, cystic fibrosis, bronchiectasis or chronic asthma) or restrictive (NMD, chest wall disorder) lung disease confirmed by a hospital consultant
  • aged > 18 years
  • established home ventilator user with ventilator prescribed for either chronic ventilatory failure or nocturnal hypoventilation
  • able to use bilevel positive pressure ventilation with Inspiratory positive airway pressure (IPAP) requirement <30cm H2O (Stellar ventilator - IPAP max 30)

Exclusion Criteria:

  • patients < 18 years
  • cognitive impairment sufficient to interfere with comprehension of the study or use of ventilator
  • poor adherence with non-invasive ventilation (<3hours/night for >10days/month)
  • Inspiratory positive airway pressure (IPAP) requirement >30cmH2O

Sites / Locations

  • Royal Brompton Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

iVAPS ventilation

Arm Description

3 months of ventilator use in iVAPS mode with data monitoring

Outcomes

Primary Outcome Measures

Change in ventilator pressure support from baseline
Pressure Support delivered by the adaptive-servo ventilator at Day 0 of exacerbation compared to the pressure support during baseline stable state.

Secondary Outcome Measures

Changes in ventilator-measured parameters from baseline
Changes in ventilator-measured parameters >15% from baseline [respiratory rate (RR), inspiratory time (Ti), pressure support (PS), Minute volume (MV), tidal volume (Vt), flow, leak, oxygen saturation (SaO2), pulse, I:E ratio, apnoea-hypopnea index (AHI), compliance]
Exacerbation as determined by a change in patients subjective symptoms
The presence of 2 or more subjective symptoms compared to baseline for 2 consecutive days; - breathlessness, increased sputum volume or sputum purulence, coryzal, wheeze or chest tightness, sore throat, cough, fever, sleep disruption, decreased physical activity
Change in peak expiratory flow rate (PEFR)>15% from baseline
Change in peak expiratory flow rate (PEFR)>15% from baseline
Exacerbation as defined by healthcare utilisation
Exacerbation defined by the requirement of antibiotics +/- steroids, GP visit, accident and emergency visit, hospital admission

Full Information

First Posted
July 16, 2012
Last Updated
October 15, 2014
Sponsor
ResMed
search

1. Study Identification

Unique Protocol Identification Number
NCT01644162
Brief Title
Ventilator Monitoring in Early Exacerbation Detection
Official Title
Use of Ventilator Monitoring for Early Detection of Exacerbations of Chronic Lung Disease
Study Type
Interventional

2. Study Status

Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
January 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ResMed

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing) in patients requiring long term home ventilation. The investigators hypothesise that acute exacerbations of patients with respiratory disease and ventilatory failure will be predicted by changes in the respiratory variables monitored and stored by ventilators during chronic home ventilator use.
Detailed Description
This pilot study is a proof of concept study investigating whether respiratory variables measured during chronic non-invasive ventilation (NIV) therapy may be used to predict a disease exacerbation. Modern ventilators used in the home for chronic respiratory failure have the ability to monitor and store respiratory variables that may worsen during exacerbations, and may potentially detect exacerbations before symptoms become apparent. Normal pressure support ventilators monitor respiratory rate which might be expected to increase with worsening disease. In patients with obstructive airways disease an increase in expiratory time may potentially be observed with worsening airways obstruction. Adaptive servo ventilators, which modulate pressure support to maintain constant minute ventilation, may increase the amount of pressure support delivered if respiratory mechanics deteriorate as a result of an exacerbation. Consenting experienced NIV users will be switched to an adaptive-servo ventilator with the capacity to monitor and store therapy data. The device being used is the Stellar 150 ventilator (Resmed, Ltd., Bella Vista, Australia) with hardware and software ability to measure variables such as respiratory rate, airflow, pressure support and leak. Patients will use the ventilator for a total of 4 months during which they will complete daily symptom diaries, including medication use and peak flow measurements. Changes in ventilator variables will be analysed and day to day variation identified. Changes will be compared with daily peak expiratory flow measures (an indication of how well the airways are functioning), patient symptoms, and healthcare utilization. Hospital admissions for exacerbations, GP consults, and healthcare team contacts will also be measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome
Keywords
Non-Invasive Positive-Pressure Ventilation, Disease Exacerbation, Respiratory Failure

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
iVAPS ventilation
Arm Type
Other
Arm Description
3 months of ventilator use in iVAPS mode with data monitoring
Intervention Type
Device
Intervention Name(s)
iVAPS ventilation
Other Intervention Name(s)
non-invasive ventilation
Intervention Description
3 months of ventilation on iVAPS mode
Primary Outcome Measure Information:
Title
Change in ventilator pressure support from baseline
Description
Pressure Support delivered by the adaptive-servo ventilator at Day 0 of exacerbation compared to the pressure support during baseline stable state.
Time Frame
up to 3 months
Secondary Outcome Measure Information:
Title
Changes in ventilator-measured parameters from baseline
Description
Changes in ventilator-measured parameters >15% from baseline [respiratory rate (RR), inspiratory time (Ti), pressure support (PS), Minute volume (MV), tidal volume (Vt), flow, leak, oxygen saturation (SaO2), pulse, I:E ratio, apnoea-hypopnea index (AHI), compliance]
Time Frame
Up to 3 months
Title
Exacerbation as determined by a change in patients subjective symptoms
Description
The presence of 2 or more subjective symptoms compared to baseline for 2 consecutive days; - breathlessness, increased sputum volume or sputum purulence, coryzal, wheeze or chest tightness, sore throat, cough, fever, sleep disruption, decreased physical activity
Time Frame
up to 3 months
Title
Change in peak expiratory flow rate (PEFR)>15% from baseline
Description
Change in peak expiratory flow rate (PEFR)>15% from baseline
Time Frame
Up to 3 months
Title
Exacerbation as defined by healthcare utilisation
Description
Exacerbation defined by the requirement of antibiotics +/- steroids, GP visit, accident and emergency visit, hospital admission
Time Frame
up to 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of obstructive (COPD, cystic fibrosis, bronchiectasis or chronic asthma) or restrictive (NMD, chest wall disorder) lung disease confirmed by a hospital consultant aged > 18 years established home ventilator user with ventilator prescribed for either chronic ventilatory failure or nocturnal hypoventilation able to use bilevel positive pressure ventilation with Inspiratory positive airway pressure (IPAP) requirement <30cm H2O (Stellar ventilator - IPAP max 30) Exclusion Criteria: patients < 18 years cognitive impairment sufficient to interfere with comprehension of the study or use of ventilator poor adherence with non-invasive ventilation (<3hours/night for >10days/month) Inspiratory positive airway pressure (IPAP) requirement >30cmH2O
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anita Simonds
Organizational Affiliation
Royal Brompton & Harefield NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Brompton Hospital
City
London
ZIP/Postal Code
SW3 6NP
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Ventilator Monitoring in Early Exacerbation Detection

We'll reach out to this number within 24 hrs